Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • IPO
      • Market News
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • November 2026
        • October 2026
        • September 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»Business News»Dr Reddy’s gets a step closer to launch its Zytorvi(toripalimab) drug for a variant of Esophageal Cancer; receives DCGI approval
    Business News

    Dr Reddy’s gets a step closer to launch its Zytorvi(toripalimab) drug for a variant of Esophageal Cancer; receives DCGI approval

    The drug is expected to strengthen Dr Reddy’s oncology portfolio, with clinical trials showing a 42% reduction in disease progression
    Abizar AttariBy Abizar AttariOctober 21, 2026No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Dr. Reddy’s received DCGI approval for Zytorvi to treat advanced esophageal cancer, following Phase 3 trials showing a 42% risk reduction
    Dr. Reddy’s received DCGI approval for Zytorvi to treat advanced esophageal cancer, following Phase 3 trials showing a 42% risk reduction
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Hyderabad, October 21: Pharma major Dr. Reddy’s Laboratories Limited has secured the approval of the Drugs Controller General of India (DCGI)’s Central Drugs Standard Control Organisation (CDSCO) for its  Zytorvi (toripalimab) drug to treat a variant of Esophageal cancer called esophageal squamous cell carcinoma (ESCC). This approval is supported by the results of the Phase 3 JUPITER-06 trial, where the drug, along with cisplatin and paclitaxel, reduced the risk of disease or death by 42% compared to chemotherapy alone. 

    Esophageal cancer has been the fourth leading cause of cancer-related deaths in India, accounting for about 8.1% of all cancer deaths. Poor diet, smokeless and smoked tobacco uise, alcohol consumption and certain environmental and socioeconomic factors have been the main risk factors for esophageal cancer. ESCC remains the predominant variant, accounting for about 80% of all esophageal cancer cases in India. Through Zytorvi, Dr. Reddy’s is aiming to expand access to the drug through its network, benefiting millions of patients pan-India.

    Globally, toripalimab has been approved by the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). With this approval in India, the drug doesn’t require patient selection on PD-L1 markers for ESCC, allowing appropriate patients to be treated regardless of their biomarker status. 

    “Following the approval of Zytorvi® in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first-line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.” M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said in a press release.

    Business Voice Now DCGI Approval Dr. Reddy’s Laboratories Limited M.V. Ramana News
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Abizar Attari
    • Website
    • Facebook
    • X (Twitter)
    • Instagram
    • LinkedIn

    I’ve always had a fascination with storytelling. Analyzing diverse perspectives and helping people understanding them simply is my life’s motto. I live to create stories that you’d love to read. When I’m not writing, you'll find me having a leisurely stroll on the beach or in the park.

    Related Posts

    Duroply Showcases its Built-to-Last Legacy

    November 14, 2026

    Austere Systems Announces H1 FY27 Results

    November 14, 2026

    ROX Hi-Tech Announces Unaudited Financial Results for H1 FY27

    November 14, 2026

    Comments are closed.

    Recent Post
    • Duroply Showcases its Built-to-Last Legacy
    • Austere Systems Announces H1 FY27 Results
    • ROX Hi-Tech Announces Unaudited Financial Results for H1 FY27
    • PAN HR Solution Limited Reports H1 FY27 Results
    • Why Colonialism Still Matters: Museum of British Colonialism to Host Online Panel Discussion on 19 November
    • Dr. R. K. Thukral and the Work of Bringing Neuropsychiatry Closer to Patients
    • From Global Recognition to Academic Excellence: LBSIM’s Continuing Journey After AACSB Accreditation
    • DEV Information Technology Reports Q2 FY27 Total Income of Rs. 63.07 Cr, Up 28 Percent YoY; H1 FY27 Total Income Reaches Rs. 107.72 Cr, Up 16 Percent YoY

    Type above and press Enter to search. Press Esc to cancel.